AngioDynamics President and CEO Eric Honroth filed a Form 4 on November 4, 2026, disclosing the acquisition of restricted stock units and performance rights on November 2, 2026, resulting in beneficial ownership of 101,193 shares of common stock.

Key Highlights

  • Two RSU grants awarded: Eric Honroth acquired 62,928 restricted stock units as part of a standard executive equity award and 38,265 restricted stock units as replacement equity for compensation forfeited at his prior employer, both on November 2, 2026.
  • Standard RSU vesting schedule: The 62,928 RSUs vest in four equal annual installments of 25% each, beginning July 15, 2027, through July 15, 2030, subject to continued employment.
  • Replacement RSU vesting schedule: The 38,265 RSUs vest in two equal annual installments of 50% each on November 2, 2027 and November 2, 2028, subject to continued employment.
  • Performance rights granted: 62,928 performance rights were also awarded, each representing a contingent right to receive one share of common stock, with payout ranging from 0% to 200% of target based on revenue, adjusted EBITDA, and relative total shareholder return over a three-year performance period.
  • Post-transaction ownership: Following the reported transactions, Honroth's direct beneficial ownership of common stock stands at 101,193 shares, according to the filing.
  • All grants at zero price: All securities were acquired at a price of $0, as reported in the filing.

AngioDynamics CEO Honroth's Equity Awards: RSUs, Replacement Grant, and Performance Rights

According to the Form 4 filed with the SEC, Eric Honroth, President and CEO of AngioDynamics Inc. (NASDAQ:ANGO) and also a Director, received two separate restricted stock unit grants and one performance rights grant on November 2, 2026. The filing was signed by Lawrence T. Weiss as Attorney in Fact on November 4, 2026.

The first grant of 62,928 RSUs is described in the filing as consistent with awards granted to other executive officers of the company. These units vest in four equal annual installments of 25% beginning July 15, 2027, and concluding July 15, 2030, contingent on continued employment through each applicable vesting date. The second grant of 38,265 RSUs was awarded "to replace equity compensation the Reporting Person forfeited at his prior employer," according to the filing. These vest in two equal installments on November 2, 2027 and November 2, 2028, also subject to continued employment.

In addition, the filing discloses a Table II entry for 62,928 performance rights. The filing states that between 0% and 200% of the target number will be earned based on a combination of the company's revenue, adjusted EBITDA, and total shareholder return relative to a peer group over a three-year performance period. The filing further notes that relative TSR performance can trigger a potential upward or downward 20% adjustment, resulting in a total potential payout of up to 240% of the target number. Any shares that do not vest at the end of the performance period will be forfeited, the filing states. All reported transactions were at a price of $0.

What Was Disclosed

AngioDynamics President and CEO Eric Honroth disclosed the receipt of 62,928 standard RSUs, 38,265 replacement RSUs, and 62,928 performance rights on November 2, 2026, bringing his direct beneficial ownership of common stock to 101,193 shares.